BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors (Q37427274)

20 August 2017

1 reference

6 November 2020

BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors (English)

1 reference

20 August 2017

chronic myeloid leukemia

1 reference

protein kinase inhibitors

6 November 2020

1 reference

2 October 2019

bcr-abl fusion proteins

1 reference

antineoplastic resistance

18 December 2019

1 reference

26 October 2020

1 reference

6 November 2020

translational peptide chain termination

1 reference

2

Hagop Kantarjian

1 reference

20 August 2017

5

Jorge Cortes

1 reference

20 August 2017

6

Maher Albitar

1 reference

20 August 2017

3

Chen-Hsiung Yeh

1 reference

20 August 2017

Wanlong Ma

1

1 reference

PMCID

2790522

20 August 2017

Zhong J Zhang

series ordinal

4

1 reference

20 August 2017

31 March 2009

11 references

20 August 2017

3 April 2019

20 June 2019

30 June 2019

2 August 2019

14 September 2019

28 September 2019

2 October 2019

18 December 2019

26 October 2020

6 November 2020

11 references

20 August 2017

3 April 2019

20 June 2019

30 June 2019

2 August 2019

14 September 2019

28 September 2019

2 October 2019

18 December 2019

26 October 2020

6 November 2020

121

1 reference

20 August 2017

1

1 reference

20 August 2017

27-31

1 reference

Creative Commons Attribution

20 August 2017

10 references

3 April 2019

20 June 2019

30 June 2019

2 August 2019

14 September 2019

28 September 2019

2 October 2019

18 December 2019

26 October 2020

6 November 2020

0 references

on focus list of Wikimedia project

ScienceSource

0 references

cites work

An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790522

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790522

The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790522

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790522

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790522

Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790522

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790522

The BCR-ABL story: bench to bedside and back

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790522

STI571 (Gleevec) as a paradigm for cancer therapy

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790522

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790522

Deletion of the Src homology 3 domain and C-terminal proline-rich sequences in Bcr-Abl prevents Abl interactor 2 degradation and spontaneous cell migration and impairs leukemogenesis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790522

Homo- and hetero-oligomerization of the c-Abl kinase and Abelson-interactor-1.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790522

Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790522

Localization of BCR-ABL to F-actin regulates cell adhesion but does not attenuate CML development

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790522

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790522

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790522

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790522

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790522

A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib

3 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790522

Circumventing Resistance to Kinase-Inhibitor Therapy

3 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790522

A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia positive acute lymphoblastic leukaemia

3 December 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/19332983

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP)

1 reference

https://pubmed.ncbi.nlm.nih.gov/19332983

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches

1 reference

https://pubmed.ncbi.nlm.nih.gov/19332983

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1159/000210060

1 reference

20 August 2017

1 reference

20 August 2017

1 reference

PMCID

2790522